Tri-VyLibra® is an AB-rated generic oral contraceptive.
Ortho Tri-Cyclen®, Tri-Estarylla™, Tri-Linyah®, Tri-Mili™, Tri-Previfem®, Tri-Sprintec®, and TriNessa®
The Product Information Sheet features a summary of all relevant product information including Tri-VyLibra® (norgestimate and ethinyl estradiol tablets, USP) 0.180 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.250 mg/0.035 mg product details, product description, NDC number, and product features.Download Now
The most common adverse reactions associated with Tri-VyLibra include headache/migraine, breast issues (including breast pain, enlargement, and discharge), vaginal infection, abdominal/gastrointestinal pain, mood disorders (including mood alteration and depression), genital discharge, changes in weight (including weight increased or decreased).
Use of COCs increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). The risk increases with age, particularly in women over 35 years of age who smoke.View Full Prescribing Information, Including Boxed Warning
Package Size: A Carton Containing 3 Packages
|ANDA||1-800-331-2632 (Ext. 74591)||andanet.com||328026|
|Morris & Dickson||1-888-376-7409||morrisdickson.com||225896|
|R & S Northeast||1-800-262-7770||rsnortheast.com||023313|